Are immunoconjugates approaching "standard of care" in AML?
1University of Washington and Fred Hutchinson Cancer Research Center, 825 Eastlake Ave E, Mailstop G3-200, Seattle, WA 98109, USA.
Abstract:
It seems clear that immunoconjugates, the combinations of antibodies with toxins, will play a role in therapy of acute myeloid leukemia (AML). It is also clear that sole emphasis on an average trial result is misplaced in AML, as the example of gentuzumab ozogamicin illustrates. Gemtuzumab added to chemotherapy can improve survival in many patients with newly diagnosed disease. The future of immunoconjugates, however, may rest on further defining the relation between CD33 and the AML stem cell and its importance in therapy. Three immunoconjugates with the cell surface antigens CD33, CD45, and CD30 will be reviewed here.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...